Live
- YSRCP manifesto is like Jagan’s resignation letter: Balakrishna
- 46 candidates in fray from Tirupati Assembly segment
- India Denies Allegations Of Plot To Assassinate Khalistani Terrorist In US
- Supreme Court Continues Hearing On Arvind Kejriwal's Arrest Challenge By ED
- Space Calendar May 2024: Rocket Launches and Stargazing Details
- Bank Holidays in May 2024: Banks in Telangana to be Closed for 8 Days
- Telangana SSC results announced, here is the link
- 100 candidates withdraw from poll fray in TS
- Visakhapatnam: Leadership development programme begins at IIM-V
- TDP never has respect for its workers, alleges Muttamsetti
Just In
The first ever Industry-Academia mission to accelerate biopharmaceutical development in India will be formally launched by the Cabinet Minister for Science and Technology, Earth Sciences, Environment, Forests and Climate Change, Dr. Harsh Vardhan in New Delhi on 30th June 2017.
The first ever Industry-Academia mission to accelerate biopharmaceutical development in India will be formally launched by the Cabinet Minister for Science and Technology, Earth Sciences, Environment, Forests and Climate Change, Dr. Harsh Vardhan in New Delhi on 30th June 2017.
The program named Innovate in India (i3) will witness an investment of USD 250 million with USD 125 million as a loan from World Bank and is anticipated to be a game changer for the Indian Biopharmaceutical industry. It aspires to create an enabling ecosystem to promote entrepreneurship and indigenous manufacturing in the sector.
Despite, these advances Indian biopharmaceutical industry is still 10-15 years behind their counterparts in the developed countries and faces stiff competition from China, Korea and others. The lacuna primarily exists due to disconnected centers of excellence, less focus on translational research and staggered funding.
There was an immediate need felt to focus on consolidated efforts to promote product discovery, translational research and early stage manufacturing in the country to ensure inclusive innovation. The aim of the Mission is to “Enable and nurture an ecosystem for preparing India’s technological and product development capabilities in biopharmaceuticals to a level that will be globally competitive over the next decade, and transform the health standards of India’s population through affordable product development”
A flagship programme in collaboration with World Bank, it promises to boost the growth curve for domestic biopharma by accelerating translation of research concepts into viable products, supporting clinical validation, enabling sustainable networks for collaboration between industry and academia, and supporting entrepreneurial ecosystem amongst many others.
Currently India has only 2.8% share in the global biopharmaceutical market, the program would elevate this to 5% resulting in an additional business opportunity of 16 Billion USD. In February, NITI Aayog, Department of Industrial Policy & Promotion (DIPP) and CII together launched a mega initiative “India Innovation Index” to rank states on innovations through country’s first online innovation index portal that will capture data on innovation from all Indian states on innovation and regularly update it in real time.
The India Innovation Index Framework is being structured based on the best practices followed in Global Innovation Index (GII) indicators and additionally by adding India-centric parameters that truly reflect the Indian innovation ecosystem.
© 2024 Hyderabad Media House Limited/The Hans India. All rights reserved. Powered by hocalwire.com